Analysts see limited Lantus impact from Tresiba's Indian launch
This article was originally published in Scrip
Executive Summary
Analysts are predicting slow growth and a minimal impact on sales of key competitor Sanofi's Lantus (insulin glargine) from the launch of Novo Nordisk's ultra-long acting once-daily insulin Tresiba (insulin degludec) on the Indian market, at least initially.